Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 GRIA1 [9] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
2 GRIA1 [9] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
3 GRIA1 [9] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
4 GRIA1 [9] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
5 GRIA2 [9] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
6 GRIA2 [9] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
7 GRIA2 [9] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
8 GRIA2 [9] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
9 GRIA3 [9] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
10 GRIA3 [9] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
11 GRIA3 [9] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
12 GRIA3 [9] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
13 GRIA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
14 GRIA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
15 GRIA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
16 GRIA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
17 GRIK1 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
18 GRIK1 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
19 GRIK2 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
20 GRIK2 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
21 GRIK3 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
22 GRIK3 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
23 GRIK4 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
24 GRIK4 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
25 GRIK5 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
26 GRIK5 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
27 GRIN1 [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
28 GRIN1 [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
29 GRIN1 [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
30 GRIN1 [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
31 GRIN1 [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
32 GRIN1 [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
33 GRIN1 [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
34 GRIN1 [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
35 GRIN2A [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
36 GRIN2A [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
37 GRIN2A [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
38 GRIN2A [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
39 GRIN2A [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
40 GRIN2A [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
41 GRIN2A [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
42 GRIN2A [10] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
43 GRIN2B [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
44 GRIN2B [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
45 GRIN2B [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
46 GRIN2B [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
47 GRIN2B [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
48 GRIN2B [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
49 GRIN2B [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
50 GRIN2B [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
51 GRIN2C [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
52 GRIN2C [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
53 GRIN2C [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
54 GRIN2C [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
55 GRIN2C [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
56 GRIN2C [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
57 GRIN2C [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
58 GRIN2C [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
59 GRIN2D [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
60 GRIN2D [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
61 GRIN2D [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
62 GRIN2D [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
63 GRIN2D [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
64 GRIN2D [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
65 GRIN2D [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
66 GRIN2D [7] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
67 KCNJ3 [6] Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D02910 Amiodarone [2] 28, 127
68 PPP3CA [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
69 PPP3CA [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
70 PPP3CA [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
71 PPP3CA [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
72 PPP3CA [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [2] 49, 222
73 PPP3CB [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
74 PPP3CB [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
75 PPP3CB [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
76 PPP3CB [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
77 PPP3CB [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [2] 49, 222
78 PPP3CC [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
79 PPP3CC [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
80 PPP3CC [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
81 PPP3CC [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
82 PPP3CC [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [2] 49, 222
83 PPP3R1 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
84 PPP3R1 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
85 PPP3R1 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
86 PPP3R1 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
87 PPP3R1 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [2] 49, 222
88 PPP3R2 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
89 PPP3R2 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
90 PPP3R2 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
91 PPP3R2 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
92 PPP3R2 [22] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [2] 49, 222
93 PRKCB [45] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, VEGF signaling pathway, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Long-term depression, Inflammatory mediator regulation of TRP channels, Insulin secretion, GnRH signaling pathway, Melanogenesis, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Insulin resistance, Growth hormone synthesis, secretion and action, Salivary secretion, Pancreatic secretion, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Leishmaniasis, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Non-small cell lung cancer, Hepatocellular carcinoma D11935 Enzastaurin [1] 168
94 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
95 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
96 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
97 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
98 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
99 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [4] 58, 96, 140, 167
100 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
101 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
102 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
103 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
104 CACNA1C [17] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226
105 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
106 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
107 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
108 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
109 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
110 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [4] 58, 96, 140, 167
111 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
112 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
113 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
114 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
115 CACNA1D [16] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226